Short Interest in Kamada Ltd. (NASDAQ:KMDA) Declines By 17.8%

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 136,757 shares, a decrease of 17.8% from the February 12th total of 166,435 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average trading volume of 63,886 shares, the days-to-cover ratio is presently 2.1 days. Based on an average trading volume of 63,886 shares, the days-to-cover ratio is presently 2.1 days. Approximately 0.4% of the shares of the company are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in Kamada during the first quarter worth about $582,000. Goldman Sachs Group Inc. purchased a new stake in Kamada in the 1st quarter valued at approximately $497,000. Essex Investment Management Co. LLC increased its position in Kamada by 22.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after purchasing an additional 72,602 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Kamada during the 2nd quarter worth approximately $472,000. Finally, Bank of America Corp DE raised its stake in shares of Kamada by 201.0% during the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after buying an additional 41,111 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KMDA. Stifel Nicolaus set a $11.00 target price on shares of Kamada in a report on Wednesday, March 11th. Wall Street Zen cut shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. HC Wainwright lifted their price objective on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Benchmark reaffirmed a “buy” rating on shares of Kamada in a report on Thursday, March 12th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Kamada Price Performance

Kamada stock opened at $8.89 on Wednesday. The business has a 50 day simple moving average of $8.50 and a 200-day simple moving average of $7.49. Kamada has a 12 month low of $5.54 and a 12 month high of $9.35. The stock has a market capitalization of $511.26 million, a PE ratio of 25.40, a price-to-earnings-growth ratio of 0.68 and a beta of 0.94.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $44.68 million during the quarter, compared to analysts’ expectations of $145.07 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%. As a group, equities research analysts anticipate that Kamada will post 0.23 EPS for the current year.

Kamada Dividend Announcement

The company also recently announced an annual dividend, which will be paid on Monday, April 6th. Stockholders of record on Monday, March 23rd will be paid a $0.25 dividend. This represents a dividend yield of 292.0%. The ex-dividend date is Monday, March 23rd.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.